Pathophysiology and Treatment of Cholangiocarcinoma

January 23 – 24, 2014
Universitätsklinikum Tübingen
CRONA Kliniken

Program

Falk Workshop

Awarded with 6 CME credits
6 credit hours (CME) have been awarded for the Falk Workshop „Pathophysiology and Treatment of Cholangiocarcinoma” by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG)
Preface

The reason why we are faced with a significant increase in cholangiocarcinoma remains unknown. Risk factors like primary sclerosing cholangitis, choledocho- and hepaticolithiasis, as well as flukes lead to chronic inflammation, and therefore cholangiocarcinomas are often associated with one of these conditions. At this meeting we will aim to learn more about the pathogenesis and multimodal treatment options of this fatal disease.

F. Lemaigre from Belgium was able to demonstrate the mechanisms of cholangiocyte differentiation and dysgenesis in humans and will give us an overview of the development and plasticity of intra- and extrahepatic cholangiocyctic cells. In molecular pathophysiology, notch signalling plays a crucial role, as recently published by the Tübingen group. The role of peribiliary glands and of the biliary tree stem/progenitor cells located in these glands promises to shed light on the pathogenesis. U. Beuers will address the question whether cholestasis itself is a prerequisite for tumour onset. We will be proud to close the first day of the meeting with a state-of-the-art lecture given by Professor Nakanuma, one of the leading pathologists in this field, who will review the pathology of biliary cancer.

The highlights of the second day will focus on current and new treatment options, starting with an interesting analogy to pancreatic cancer. Finally, the last session will be dedicated to new molecular endoscopic diagnostics as well as new treatment modalities and future developments. For surgery, cholangiocarcinomas remain a challenge, independently of intra- or extrahepatic origin. Due to the fact that cholangiocarcinomas grow along the periductal space, in the majority of cases extended hepatectomies are mandatory to achieve tumour-free margins. New concepts in the hands of experienced hepato-biliary surgeons allow an R0 resection rate in 60%-80% of the cases. In locally advanced extrahepatic biliary cancers without lymph node or haematogenic metastases, liver transplantation following a multimodal treatment approach is associated with good long-term survival.

We look forward to welcoming leading international experts in the field of cholangiocarcinoma and you to Tübingen to share the current knowledge and hot topics as well as new strategies at the FALK/GASL Meeting in 2014.

A. Königsrainer
Pathophysiology and Treatment of Cholangiocarcinoma

January 23 – 24, 2014
Universitätsklinikum Tübingen
CRONA Kliniken
Tübingen, Germany

The 30th Annual Meeting of the German Association for the Study of the Liver will follow the Falk Workshop: January 24, 13.30 h to January 25, 14.30 h

Scientific Organization:
A. Königsrainer, Tübingen (Germany)
N. P. Malek, Tübingen (Germany)

Congress Secretaries:
J. Glatzle, Tübingen (Germany)
R. R. Plentz, Tübingen (Germany)

Congress Venue:
Universitätsklinikum Tübingen
CRONA Kliniken
Hoppe-Seyler-Str. 3
72076 Tübingen
Germany

Information:
Prof. Dr. Alfred Königsrainer
Klinik für Allgemeine-, Viszeral- und Transplantationschirurgie
Universitätsklinikum Tübingen
Hoppe-Seyler-Str. 3
72076 Tübingen
Phone: +49 (0) 7071 / 298 66 20
Fax: +49 (0) 7071 / 29 55 88
Email: GASL@med.uni-tuebingen.de

Official Language:
English

Poster Session:
For details see page 8
Thursday, January 23, 2014

12.30 Welcome lunch with poster session

13.30 Welcome

A. Königsrainer, Tübingen

Session I
Molecular basis of biliary cancer formation

Chair: B. Sipos, Tübingen; C. P. Strassburg, Bonn

13.40 Development and plasticity of biliary cells
F. Lemaigre, Brussels

14.10 Molecular mechanisms of CCC pathophysiology
L. Zender, Tübingen

14.40 The role of stem cells in cholangiocarcinoma
D. Alvaro, Rome

15.10 Cholestasis – A necessary pre-requisite for cholangiocellular carcinoma formation?
U. Beuers, Amsterdam

15.40 Coffee break with poster session

Session II
Predisposing conditions

Chair: U. Beuers, Amsterdam; R. R. Plentz, Tübingen

16.10 The genetics of primary sclerosing cholangitis
T. H. Karlsen, Oslo

16.40 Biliary stones and cholangiocarcinoma formation
F. Lammert, Homburg

17.10 Inflammatory biliary disease – From mouse models to new treatment options
M. Trauner, Vienna

17.40 Pathophysiology of primary sclerosing cholangitis
C. P. Strassburg, Bonn

18.10 Pathology of bile duct carcinoma
Y. Nakanuma, Kanazawa
Friday, January 24, 2014

Session III
Targeted therapies in CCC
Chair: N. P. Malek, Tübingen; P. Neuhaus, Berlin

9.00 Current treatment of CCC – Where do we stand? A. Vogel, Hannover

9.30 What can we learn from pancreatic cancer? R. Schmid, Munich

10.00 New treatment strategies for CCC – What can we hope for? R. R. Plentz, Tübingen

10.30 Coffee break with poster session

Session IV
Interventional treatment of CCC
Chair: A. Königsrainer, Tübingen; R. Schmid, Munich

11.00 Biliary endoscopy – Molecular diagnosis and treatment options M. Götz, Tübingen

11.30 Surgical treatment of CCC – What are the options? P. Neuhaus, Berlin

12.00 Is liver transplantation back in the treatment of CCC? S. Nadalin, Tübingen

12.30 Farewell

12.40 Farewell lunch

13.30 Opening of the Annual Meeting of the GASL
Poster Session

Posters will be exhibited on January 23–24, 2014, at the Universitätsklinikum Tübingen, Kasino Kliniken Berg, building 520, 1st floor. The authors will be in attendance during coffee and lunch breaks on both days.

1. Expression of hypoxia inducible factors in a rat model of thioacetamide (TAA)-induced chronic liver damage and cholangiocarcinoma
   S. Ahmad, N. Naz, I.A. Malik, F. Moriconi (Göttingen, DE)

2. Age-related changes in the antioxidant system of the liver
   N. Bork, B. Burkhardt, W. Yang, B. Husen, A. Nüssler (Tübingen, Saarbrücken, DE)

3. Evaluation of a chip-based 3D culture system for the use of primary human hepatocytes in drug toxicity testing
   B. Burkhardt, N. Hebel, S. Giselbrecht, E. Gottwald, R. Zantl, A. Nüssler (Tübingen, Karlsruhe, Munich, DE)

4. Hypoxia influences expression of genes involved in angiogenesis and EMT in HCC cells
   S. Buschauer, C. Hellerbrand (Regensburg, DE)

5. Monoallelic MUTYH hotspot mutations do not confer substantial genetic susceptibility to cholangiocarcinoma
   M. Casper, M. Acalovschi, F. Lammert, V. Zimmer (Homburg, DE; Cluj-Napoca, RO)

6. Upregulation of SPRED and SPROUTY2 in the pathogenesis of chronic liver disease
   B. Czech, C. Hellerbrand (Regensburg, DE)

7. Y-box-binding protein 1 is a critical mediator in cholangiocarcinoma
   S. Dooley, H. Liu, P.R. Mertens, H.-L. Weng (Mannheim, Magdeburg, DE)

8. Sustained virological response is low in diabetic Egyptian chronic hepatitis C patients and zero % in patients who developed DM during Peg interferon/ribavirin therapy
   M.S. Elkady, I. Awadeen, H. Elfiky, E. Saeed, M. Elseesey, W. Shaheen (Benha, Elagoza Cairo, EG)

9. BRAF V600E specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
10. Expression pattern of epithelial-mesenchymal transition-associated miRNAs in biliary tract cancer: A clinical and pathological approach
R. Illig, T. Kiesslich, R. Kemmerling, B. Alinger, E. Klieser, F. Berr, D. Neureiter (Salzburg, AT)

11. Establishment of a human in vitro model to evaluate the immune response of Kupffer cells after hepatic tissue damage
V. Kegel, E. Pfeiffer, T. Schulz, B. Burkhardt, D. Seehofer, A. Nüssler, G. Damm (Berlin, Tübingen, DE)

12. Effects of glucose levels on lipid metabolisms in hepatocellular carcinoma cells in vitro
A. Koch, M. Müller, C. Hellerbrand (Regensburg, DE)

13. Metal stent placement at ERCP in a DGH – Patient selection according to prognosis
S. Kotha, G. Bird (Maidstone, GB)

14. Analysis of natural killer cell receptor G2D (NKG2D) variant in a cohort of European patients with cholangiocarcinoma
M. Krawczyk, F. Mihalache, M. Acalovschi, F. Lammert, V. Zimmer (Homburg, DE; Cluj-Napoca, RO)

15. Decreased Smad3 phosphorylation at linker serine 213 is associated with poor prognosis of patients with intrahepatic cholangiocarcinoma
J. Li, S. Munker, I. Königsrainer, B. Sipos, R. Liebe, Q. Li, Q. Sun, D. Dobrev, A. Königsrainer, S. Nadalin, S. Dooley, H.-L. Weng (Hamburg, Mannheim, Tübingen, DE)

16. The extracellular proteinase Expi/Wfdc18 is induced by toll like receptor 9 (TLR9) in macrophages and enhances hepatic fibrogenesis
R. Liebe, R. Hall, S. Dooley, F. Lammert (Homburg, Mannheim, DE)

17. Lipid accumulation enhances the susceptibility for oxaliplatin-induced hepatic injury
A. Mahli, W.E. Thasler, C. Hellerbrand (Regensburg, Munich, DE)

18. Early induction of CXC-, CC-chemokines and of cytokines before neutrophil granulocytes and macrophage recruitment in different regions of the rat liver after single-dose thioacetamide (TAA)-administration
I.A. Malik, F. Moriconi, A. Amanzada (Göttingen, DE)

19. FAT/CD36: The main responsible protein for fat accumulation in rat liver after direct single-dose irradiation?
G. Martius, S.M. Alwahsh, M. Rave-Fränk, C.F. Hess, H. Christiansen, I. Malik (Göttingen, Hannover, DE)
20. PRC2 inhibition may directly target putative cancer stem cells in biliary tract cancer cell lines
   C. Mayr, A. Wagner, R. Illig, M. Pichler, F. Berr, D. Neureiter, T. Kiesslich (Salzburg, AT)

21. Changes in hepatic iron uptake in a rat model of thioacetamide-induced restorable hepatic damage
   N. Naz, S. Ahmad, N. Sheikh, I. Malik, G. Ramadori (Göttingen, DE; Lahore, PK)

22. Isolation of human liver cells for the establishment of functional co-culture and tissue engineering liver models
   E. Pfeiffer, V. Kegel, B. Burkhardt, D. Seehofer, A. Nüssler, G. Damm (Berlin, Tübingen, DE)

23. The study of polarimetric spectrophotometry as a possible screening tool for cholangiocarcinoma

24. Growth of human cholangiocellular carcinoma cells and expression of proangiogenic factors is affected by Nexavar treatment
   E. Raskopf, A. Vogt, T. Sauerbruch, C.P. Strassburg, V. Schmitz (Bonn, Göttingen, Bad Kreuznach, DE)

25. Changes in serum protein profile due to iron- and copper-induced toxicity in Rattus norvegicus
   N. Sheikh, A. Farrukh, A. Syed Abbas (Lahore, PK)

26. Histopathological and histochemical alterations due to acute iron and copper intoxication in rat liver
   N. Sheikh, A. Farrukh, M. Shafiq, H. Manzoor, Q. Mushtaq (Lahore, PK)

27. Impact of acute iron & copper intoxication on biochemical liver function in Wistar rat
   N. Sheikh, A. Farrukh, T. Akhtar, K. Ur-Rehman (Lahore, PK)

28. Genetically engineered Upcyte® hepatocytes as a capable application for energy metabolism experiments in in vitro liver cells systems
   S. Sperling, N. Herzog, M. Hansen, J.-H. Küpper, D. Seehofer, G. Damm (Berlin, Senftenberg, DE)

29. Inhibition of cyclooxygenase-2 in vitro induces apoptosis and decreases proliferation of the human cholangiocarcinoma cells
   A. Sydorchuk, L. Sydorchuk, P. Fomin, R. Sydorchuk, I. Sydorchuk, O. Plehutsa, S. Levites, A. Vynohradsky (Chernivtsi, Kyiv, UA)
30. In vitro study of vascular endothelial growth factor inhibition in cholangiocarcinoma
   L. Sydorchuk, R. Sydorchuk, P. Fomin, A. Sydorchuk, I. Sydorchuk, O. Plehutsa, S. Levites, A. Vynohradskyy (Chernivtsi, Kyiv, UA)

31. In vitro influence of peroxisome proliferator-activated receptor-gamma activation on cholangiocarcinoma cells
   R. Sydorchuk, L. Sydorchuk, J. Yarynich, A. Sokolenko, A. Sydorchuk, I. Sydorchuk, O. Plehutsa (Chernivtsi, UA)

32. MicroRNAs associated with the efficacy of photodynamic therapy in biliary tract cancer cell lines

33. No liver malignancies in the HCV-1b (anti-D) Leipzig cohort after more than three decades
   M. Wiese, F. Richter (Leipzig, DE)

34. Decline of DNA repair ability is paralleled by decreased autophagy in rat aging liver
   W. Yang, B. Burkhardt, P. Prückl, A. Nüssler (Tübingen, Saarbrücken, DE)
List of Speakers, Moderators and Scientific Organizers

**Dr. Domenico Alvaro**  
Università di Roma  
Policlinico Umberto  
Il Cattedra di Gastroenterologia  
Viale dell’ Universita’, 37  
00185 Rom  
Italy  
domenico.alvaro@uniroma1.it

**Prof. Dr. Ulrich Beuers**  
Univ. van Amsterdam, Tytgat Inst. for Liver & Intestinal Research  
Department of Gastroenterology & Hepatology, B1-244.2  
Meibergdreef 9  
1105 AZ Amsterdam  
The Netherlands  
u.h.beuers@amc.uva.nl

**PD Dr. Jörg Glatzle**  
Allgemeine Chirurgie  
Universitätsklinikum Tübingen  
Hoppe-Seyler-Str. 3  
72076 Tübingen  
Germany  
joerg.glatzle@med.uni-tuebingen.de

**Prof. Dr. Martin Götz**  
Innere Medizin I  
Universitätsklinikum Tübingen  
Otfried-Müller-Str. 10  
72076 Tübingen  
Germany  
mgoetz@mail.uni-mainz.de

**Dr. Tom Hemming Karlsen**  
University of Oslo  
Rikshospitalet  
Norwegian PSC Res. Ctr.  
Medical Department  
0027 Oslo  
Norway  
tomhk@ulrik.uio.no

**Prof. Dr. Alfred Königsrainer**  
Allgemeine Chirurgie  
Universitätsklinikum Tübingen  
Hoppe-Seyler-Str. 3  
72076 Tübingen  
Germany  
alfred.koenigsrainer@med.uni-tuebingen.de

**Prof. Dr. Frank Lammert**  
Klinik für Innere Medizin II  
Universitätsklinikum des Saarlandes  
Kirberger Str. 100  
66424 Homburg  
Germany  
frank.lammert@uks.eu

**Dr. Frederic Lemaigre**  
De Duve Institute and Université catholique de Louvain  
Avenue Hippocrate 75, 1st floor  
1200 Brüssel  
Belgium  
lemaigre@horm.ucl.ac.be

**Prof. Dr. Nisar P. Malek**  
Innere Medizin I  
Universitätsklinikum Tübingen  
Otfried-Müller-Str. 10  
72076 Tübingen  
Germany  
nisar.malek@med.uni-tuebingen.de

**PD Dr. Silvio Nadalin**  
Allgemeine Chirurgie  
Universitätsklinikum Tübingen  
Hoppe-Seyler-Str. 3  
72076 Tübingen  
Germany  
silvio.nadalin@med.uni-tuebingen.de
Prof. Dr. Yasuni Nakanuma
Department of Human Pathology
Kanazawa University Graduate School of Medicine
University Hospital
13-1 Takara-machi
Kanazawa, 920-8641
Japan
pbcpsc@kenroku.kanazawa-u.ac.jp

Prof. Dr. Peter Neuhaus
Allgemein- und Viszeralchirurgie
Charité Universitätsmedizin
Campus Virchow-Klinikum (CVK)
Augustenburger Platz 1
13353 Berlin
Germany
peter.neuhaus@charite.de

PD Dr. Ruben R. Plentz
Innere Medizin I
Universitätsklinikum Tübingen
Otfrid-Müller-Str. 10
72076 Tübingen
Germany
ruben.plentz@med.uni-tuebingen.de

Prof. Dr. Roland Schmid
II. Medizinische Klinik und Poliklinik
Ismaninger Str. 22
81675 München
Germany
roland.schmid@lrz.tu-muenchen.de

Prof. Dr. Bence Sipos
Institut für Pathologie und Neuropathologie
Eberhard-Karls-Universität Tübingen
Liebermeisterstraße 8
72076 Tübingen
Germany
bence.sipos@med.uni-tuebingen.de

Prof. Dr. Christian P. Strassburg
Medizinische Klinik I
Universitätsklinikum Bonn
Sigmund-Freud-Str. 25
53127 Bonn
Germany
christian.straussburg@ukb.uni-bonn.de

Prof. Dr. Michael Trauner
Medizinische Universität Wien
Klinische Abteilung für Gastroenterologie & Hepatologie
Währinger Gürtel 18-20
1090 Wien
Austria
michael.trauner@meduniwien.ac.at

Prof. Dr. Arndt Vogel
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30625 Hannover
Germany
vogel.arndt@mh-hannover.de

Prof. Dr. Lars Zender
Medizinische Klinik
Innere Medizin I
Sektion für Gastrointestinale Onkologie
Universitätsklinikum Tübingen
Otfrid-Müller-Strasse 10
72076 Tübingen
Germany
lars.zender@med.uni-tuebingen.de
Congress Office

During Falk Workshop

Universitätsklinikum Tübingen
CRONA Klinikum
Hoppe-Seyler-Str. 3
72076 Tübingen
Germany

Telephone: +49 (0)175/7795327

Opening Hours:
Thursday, January 23, 2014 10.00 – 18.30 h
Friday, January 24, 2014 8.00 – 12.30 h

Congress Fees

The participation in the Falk Workshop is free of charge, however, registration is mandatory.

Refreshments during coffee breaks on January 23 and 24, lunches on January 23 and 24, dinner on January 23 and a copy of the abstract volume of the Falk Workshop are also free of charge.

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

Hotel Accommodation

www.hotel.de or www.hrs.com

Airport

Stuttgart Airport (approx. 37 km from the congress venue)
www.stuttgart-airport.com

The 30th Annual Meeting of the German Association for the Study of the Liver will take place immediately following the Falk Workshop (January 24 and 25, 2014).
Directions to Universitätsklinikum Tübingen

Einfahrt Klinikgelände
Die Zahlenangaben entsprechen den Gebäudenummern

Crona Kliniken
Anästhesiologie
Chirurgie
Neurochirurgie
Neurologie
Orthopädie
Radiologie
Radioonkologie
THG-Chirurgie
Urologie

Kinderrklinik

Gesundheitszentrum
Medizinisches Trainings- und Rehabilitationszentrum
Psychosomatische Tagesklinik
Sportmedizin

Medizinische Klinik
Blutspendezentrale
Konferenzzentrum
Casino, Cafeteria
Nuklearmedizin
Hals-Nasen-Ohrenklinik
Medizinische Mikrobiologie
Medizinische Virologie
General Information:

FALK FOUNDATION e.V.

Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department
Telephone: +49(0)761/1514-0
Telefax: +49(0)761/1514-359
E-mail: symposia@falkfoundation.de
www.falkfoundation.de